Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.10 USD
Change Today +0.37 / 6.46%
Volume 1.7K
ARGS On Other Exchanges
As of 1:22 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

argos therapeutics inc (ARGS) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/6/15 - $10.56
52 Week Low
08/14/15 - $4.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

argos therapeutics inc (ARGS) Related Businessweek News

No Related Businessweek News Found

argos therapeutics inc (ARGS) Details

Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in phase 2 clinical trial for the treatment of Human Immunodeficiency Virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.

113 Employees
Last Reported Date: 03/31/15
Founded in 1997

argos therapeutics inc (ARGS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $543.6K
Chief Operating officer and Vice President of...
Total Annual Compensation: $357.0K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: $382.5K
Compensation as of Fiscal Year 2014.

argos therapeutics inc (ARGS) Key Developments

Argos Therapeutics, Inc. - Special Call

To review current clinical research landscape in metastatic renal cell carcinoma (mRCC) and provide an update on the company's lead product candidate, AGS-003, and the pivotal ADAPT phase 3 clinical trial for the treatment of mRCC

Argos Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 04:30 PM

Argos Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 04:30 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Shawn Leland, Director, Corporate Development & Strategy.

Argos Therapeutics, Inc. Announces Executive Changes

Argos Therapeutics, Inc. announced the appointment of Robert F. Carey to the company's board of directors. Mr. Carey will replace Mr. Jean Lamarre, who has served on the board since 2013, as a director and as chairman of the company's audit committee. Currently serving as executive vice president and chief business officer for Horizon Pharma plc, Mr. Carey has more than three decades of experience in healthcare investment banking, business development and investor relations. He has served as an advisor on greater than $15 billion in financings, as well as numerous mergers and acquisitions. He was also responsible for starting and managing JMP Securities' healthcare group.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARGS:US $6.10 USD +0.37

ARGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $10.15 USD -0.36
Eurocine Vaccines AB kr1.79 SEK -0.06
Genocea Biosciences Inc $6.33 USD -0.06
GenVec Inc $2.02 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation ARGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 111.7x
Price/Book 23.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 52.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARGOS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at